ClinicalTrials.gg
TerminatedNCT00395967Updated May 1, 2015Results posted

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

A Phase 2 interventional study of G-CSF plus plerixafor in Multiple Myeloma and Lymphoma, Non-Hodgkin's, sponsored by Genzyme, a Sanofi Company. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-05-01.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Why this study was terminated
Enrollment terminated in 2005 to focus on Phase 3 study enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
28th of 28
5 · median 38
Started
2005
with 4 others
Phase 2
17 of 28
none open now
Registered
8th of 28
by date
Lead sponsor
7 of 28
Genzyme, a Sanofi Company

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 28th largest by enrollment, is one of 5 that started in 2005, is one of 17 in phase 2, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10\^6 CD34+ cells/kg within 3 apheresis days. Patients with NHL and MM were eligible to enter the study if they had undergone cyto-reductive chemotherapy, were to undergo autologous transplantation, and met the inclusion/exclusion criteria.

The purpose of this protocol was to determine whether plerixafor in combination with Granulocyte Colony Stimulating Factor (G-CSF) can increase the circulating levels of peripheral blood stem cells (PBSCs) in patients whose peripheral CD34+ counts remain low after treatment with G-CSF alone, whether it was safe, and whether transplantation with the apheresis product was successful, as measured by time to engraftment of polymorphonuclear leukocytes (PMNs) and platelets (PLTs).

Read the detailed description

A Phase 2, single-center, open-label study to assess the safety and hematological activity of plerixafor in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10\^6 CD34+ cells/kg within 3 apheresis days. The only change to the standard of care was the addition of plerixafor to a G-CSF mobilization regimen on the day prior to apheresis.

Following screening procedures, eligible patients undergo mobilization with G-CSF (10 µg/kg every day) for 5 days and their peripheral blood (PB) CD34+ cell count was measured on the fifth day.

On Day 5, if the patient's peripheral CD34+ cell count was \<5 cells/µl or ≥20 cells/µl, the patient did not enter this study and was treated as per the policy of the study site.

On Day 5, if the patient's peripheral CD34+ cell count was 5 to 7 cells/µl (inclusive), the patient did not undergo apheresis that day, but did receive plerixafor (240 µg/kg) that evening and G-CSF followed by apheresis the next morning. The evening dose of plerixafor followed the next morning by G-CSF and apheresis was repeated for up to a total of 3 days of apheresis or until ≥5*10\^6 cells/kg are collected.

On Day 5, if the patient's peripheral CD34+ cell count was 8 to 19 cells/µl (inclusive), then he/she underwent apheresis that day. If this apheresis yield was \<1.3*10\^6 CD34+ cells/kg, then the patient was predicted to be unlikely to collect ≥2*10\^6 CD34+ cells/kg in ≥3 days of apheresis and received plerixafor (240 µg/kg) that evening. However, if the apheresis yield on Day 5 was ≥1.3*10\^6 CD34+ cells/kg, then the patient did not enter the study.

The next morning (Day 6), eligible patients received G-CSF (10 µg/kg) and began apheresis approximately 10 to 11 hours after the previous evening plerixafor dose. If the apheresis yield was at least double the apheresis yield on Day 5, then the patient received another 10:00 pm dose of plerixafor and underwent apheresis again the next morning (Day 7) after receiving G-CSF. The evening dose of plerixafor followed the next morning by G-CSF and apheresis was repeated for up to a total of 3 days of apheresis or until ≥5*10\^6 cells/kg were collected.

All patients, after the completion of apheresis procedures (or after ≥5*10\^6 cells/kg were collected), received high-dose chemotherapy in preparation for transplantation. Patients were transplanted with cells collected after receiving plerixafor with G-CSF. However, if there were insufficient cells, cells collected after receiving plerixafor with G-CSF could be pooled with cells collected after receiving G-CSF alone.

Hematological activity of plerixafor was evaluated by assessing the number of CD34+ cells harvested during apheresis.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin's

Keywords

  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • stem cell mobilization
  • autologous transplantation
  • AMD3100
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM)
  • Eligible for transplantation
  • \<=3 prior regimens of chemotherapy (Rituxan is not considered chemotherapy for the purpose of this study)
  • >4 weeks since last cycle of chemotherapy (Rituxan is not considered chemotherapy for the purpose of this study)
  • Total dose of melphalan ≦200 mg
  • Eastern Co-operative Oncology Group () performance status of 0 or 1
  • White blood cell (WBC) count >3.0*10\^9/L prior to first dose of G-CSF
  • Absolute polymorphonuclear leukocyte (PMN) count >1.5*10\^9/L prior to first dose of G-CSF
  • (PLT) count >100*10\^9/L prior to first dose of granulocyte colony-stimulating factor (G-CSF)
  • Serum creatinine ≥2.2 mg/dL
  • , SGPT and total \<2 times (ULN)
  • Negative for
  • CD34+ cell count between 5 and 19 CD34+ cells/ml after 5 days of mobilization with G-CSF alone

Exclusion criteria

Exclusion Criteria (Abbreviated List):

  • A co-morbid condition which, in the view of the investigator, renders the patient at high risk from treatment complications
  • Failed previous stem cell collection or collection attempts
  • A residual acute medical condition resulting from prior chemotherapy
  • Active or carcinomatous meningitis
  • Active infection requiring antibiotic treatment
  • Received prior radio-immunotherapy with Zevalin or Bexxar
  • Received bone-seeking radionuclides (e.g., holmium)
  • Received thalidomide, dexamethasone, and/or Velcade within 7 days prior to the first dose of G-CSF
  • History of ventricular arrhythmias, including (ECG)-documented premature ventricular contractions (PVCs), during the last 3 years
  • Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase
  • Had an apheresis yield >1.3*10\^6 CD34+ cells/kg on Day 5 (Applicable only to patients who, after 5 days of G-CSF mobilization, have peripheral blood (PB) CD34+ count of 8-19 cells/µl inclusive).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    All Patients

    Patients who were predicted to be unable to mobilize a minimum number of cells (≥2\*10\^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.

    Drug: G-CSF plus plerixafor

Interventions

  • DrugG-CSF plus plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.

    Also known as: Mozobil, AMD3100

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days

    The number of patients with a circulating CD34+ count \>= 5 and \< 20 cells/ml after 5 days of mobilization with G-CSF alone who achieved cumulative apheresis yields of ≥2\*10\^6 CD34+ cells/kg within 3 days of apheresis after receiving G-CSF plus plerixafor. Outcome was based on laboratory results from a central lab.

    Time frame: approximately days 6-9

Secondary outcomes

  1. Overall Participants Counts of Adverse Events

    Numbers of participants with adverse events (AEs) collected from Day 1 (start of G-CSF Mobilization) to 12 months after transplantation. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.

    Time frame: up to 13 months

  2. The Fold Increase in Peripheral Blood CD34+ Cells Following the First Dose of Plerixafor

    The fold increase was measured by fluorescence activated cell sorting (FACS) analysis and expressed as a ratio. Fold increase = pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL). This study was terminated early and analysis was not done.

    Time frame: Days 5-6

  3. Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

    The median number of days to PMN engraftment criteria was PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that criteria were met. This study was terminated early and analysis was not done.

    Time frame: 2 months

  4. Number of Days to Platelet (PLT) Engraftment

    The median number of days to platelet (PLT) engraftment criteria was ≥ 20\*10\^9/L platelets without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that criteria were met. This study was terminated early and analysis was not done.

    Time frame: 2 months

  5. Graft Durability at 12 Months After Transplantation

    Participants with durable grafts. Graft durability was assessed by complete blood count (CBC) and differential analysis at 12 months post-transplantation. This study was terminated early and analysis was not done.

    Time frame: 13 months

07

Results

Posted Aug 13, 2010
Limitations and caveats
Limited enrollment due to early termination of the study.

Participant flow

Study enrollment began in April 2005 and the study was terminated in August 2006. Target enrollment was 15 patients, however the trial was terminated early after five patients were enrolled.

Treatment Period
Participant flow — Treatment Period
MilestoneAll Patients
Started5
Completed4
Not completed1
Withdrew: Failed mobilization1
Follow-up Period
Participant flow — Follow-up Period
MilestoneAll Patients
Started5
Completed3
Not completed2
Withdrew: Death1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days

The number of patients with a circulating CD34+ count \>= 5 and \< 20 cells/ml after 5 days of mobilization with G-CSF alone who achieved cumulative apheresis yields of ≥2\*10\^6 CD34+ cells/kg within 3 days of apheresis after receiving G-CSF plus plerixafor. Outcome was based on laboratory results from a central lab.

Time frame:
approximately days 6-9
Reported as:
Number · participants
Number of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days
participantsAll Patients
Participants with ≥2*10^6 CD34+ cells/kg3
Participants with <2*10^6 CD34+ cells/kg2
SecondaryOverall Participants Counts of Adverse Events

Numbers of participants with adverse events (AEs) collected from Day 1 (start of G-CSF Mobilization) to 12 months after transplantation. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.

Time frame:
up to 13 months
Reported as:
Number · participants
Overall Participants Counts of Adverse Events
participantsAll Patients
Participants Reporting At Least One AE5
Participants Reporting a Severe AE4
Participants Reporting a Life-threatening AE2
AE Relation to Drug: Not Related or Probably Not3
AE Relation to Drug: Possibly Related2
AE Relation to Drug: Probably or Definitely Relate0
Serious Adverse Events4
AEs Leading to Discontinuation0
SecondaryThe Fold Increase in Peripheral Blood CD34+ Cells Following the First Dose of Plerixafor

The fold increase was measured by fluorescence activated cell sorting (FACS) analysis and expressed as a ratio. Fold increase = pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL). This study was terminated early and analysis was not done.

Time frame:
Days 5-6

No measurements were reported for this outcome.

SecondaryNumber of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

The median number of days to PMN engraftment criteria was PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that criteria were met. This study was terminated early and analysis was not done.

Time frame:
2 months

No measurements were reported for this outcome.

SecondaryNumber of Days to Platelet (PLT) Engraftment

The median number of days to platelet (PLT) engraftment criteria was ≥ 20\*10\^9/L platelets without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that criteria were met. This study was terminated early and analysis was not done.

Time frame:
2 months

No measurements were reported for this outcome.

SecondaryGraft Durability at 12 Months After Transplantation

Participants with durable grafts. Graft durability was assessed by complete blood count (CBC) and differential analysis at 12 months post-transplantation. This study was terminated early and analysis was not done.

Time frame:
13 months

No measurements were reported for this outcome.

Adverse events

Collected over All treatment-emergent AEs are summarized. An event whose onset was on or after the first administration of study treatment (either G-CSF or plerixafor) was considered treatment-emergent.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Patients—4/5 (80%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventAll Patients
Acute myocardial infarctionCardiac disorders1/5
VomitingGastrointestinal disorders1/5
Disease progressionGeneral disorders1/5
Renal failure acuteRenal and urinary disorders1/5
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/5
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAll Patients
NauseaGastrointestinal disorders3/5
CoughRespiratory, thoracic and mediastinal disorders3/5
HeadacheNervous system disorders2/5
Abdominal painGastrointestinal disorders1/5
ConstipationGastrointestinal disorders1/5
ChillsGeneral disorders1/5
FatigueGeneral disorders1/5
PyrexiaGeneral disorders1/5
InfectionInfections and infestations1/5
HypokalaemiaMetabolism and nutrition disorders1/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Patients
Mean52.2 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)All Patients
Female2
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Patients
Caucasian5
Disease Diagnosis
Disease Diagnosis(participants)All Patients
Multiple Myeloma (MM)1
Non-Hodgkin's lymphoma (NHL)3
Hodgkin's disease (HD)1
08

Study locations

1 site
  • Duke University Medical Center - Adult BMT Program
    Durham, North Carolina 27705, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jul 2005 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2006
First posted
Nov 6, 2006
Start
Apr 2005
Primary completionActual
Jul 2005
CompletionActual
Aug 2006
Results first posted
Aug 13, 2010
Last update
May 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00395967
First posted
Nov 6, 2006
Start date
Apr 2005
Primary completion
Jul 2005
Completion
Aug 2006
Results posted
Aug 13, 2010
Last update
May 1, 2015

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion